ArisGlobal has announced the extension of its strategic partnership with Sitero.

This collaboration integrates Sitero's unified eClinical technology platform - including Mentor EDC/ePRO, RTSM, eConsent, Payments and CTMS/eTMF - into ArisGlobal's LifeSphere R&D technology suite.

This expanded partnership offers ArisGlobal and Sitero's global life sciences customers a solution unmatched in the industry today. The combined solution allows for a seamless experience across the entire R&D IT ecosystem.

This integrated platform eliminates the need for double data entry and data reconciliation; utilizes intelligent ingestion of relevant case data; and streamlines end-to-end data and document processing across research and development. The resulting enhanced data harmonization leads to increased accuracy, efficiency, and subject safety throughout the trial.

"ArisGlobal's strategic initiatives and investments are prioritized based on end-user benefits and process optimization to deliver true value and return on investment (ROI) for our Global partners," shared Aman Wasan, CEO at ArisGlobal.

"LifeSphere has invested in powerful platforms in Safety, Regulatory, Medical Affairs and Quality, powered by LifeSphere NavaX, our next-generation cognitive computing engine that delivers enhanced value with advanced Gen AI and LLM solutions. Sitero has developed an equally formidable eClinical platform that includes advanced clinical and data management capabilities. Our integration enables us to jointly offer the most innovative and comprehensive life sciences R&D technology platform," Wasan added.

Sankesh Abbhi, CEO of Sitero, added, "By harnessing our deep business process expertise and advanced automation consulting capabilities, we are bringing to life a cutting-edge clinical platform for pharmaceutical companies. This expanded partnership with ArisGlobal enables us to offer even greater value by delivering a fully-integrated solution across the Mentor and LifeSphere platforms."

This expanded technology partnership builds from the companies' existing implementation partnership that was previously announced in February 2024.